Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Enters manufacturing agreement with Ausun Pharma for lead asset MB-204.
July 22, 2021
By: Tim Wright
Marvel Biotechnology has reported a milestone in the development of its lead compound MB-204, entering into a current good manufacturing process (cGMP) manufacturing agreement with Zhejiang Ausun Pharmaceutical. The partnership is for the supply of Marvel’s lead asset MB-204 for toxicology studies and clinical trials. MB-204 has potential application for the treatment of depression and anxiety, Alzheimer’s, ADHD and non-neurological diseases such as cancer and non-alcoholic steatohepatitis. Ausun was chosen and the agreement entered into as a result of an extensive Request for Proposal (RFP) process and negotiations undertaken by Marvel Biotechnology for the pilot manufacturing of its lead compound MB-204. The company said Ausun possesses the expertise in process development and custom manufacturing of active pharmaceutical ingredients (APIs), intermediates and formulated products; and will develop the chemical process and manufacture of Marvel’s MB-204 API formulation. “This is a major science milestone event for the company as we work to achieve and develop our lead asset MB-204 for clinical testing and commercialization,” said Mark Williams, president and chief science officer, Marvel. “This program has now commenced and follows after the completion of our reverse take-over and amalgamation transaction with our partners at Alphanco, and the recommencement of trading on the TSXV last week as Marvel Biosciences Corp. We look forward to updating the market on our progress and the lead asset, MB-204.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !